# A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma

> **NCT01030783** · PHASE3 · COMPLETED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 517 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** tivozanib (AV-951)
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01030783
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-07
- **Final completion:** 2013-06
- **Target enrollment:** 517 (ACTUAL)
- **Last updated:** 2019-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01030783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01030783, "A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01030783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*